Drug development is a high-risk endeavor, typically requiring 12 years and $2 billion to bring a single product to market, with a 90% failure rate. In this episode, Saurabh Mukherjea and Kumar Mayank discuss how Artificial Intelligence is being used to navigate these challenges by solving long-standing biological puzzles and streamlining the preclinical research phase.
The Challenge of Protein Folding
For decades, scientists faced Levinthal's Paradox, which suggests that a protein chain can take more shapes than there are atoms in the universe. Understanding these 3D structures is essential for developing drugs to treat malfunctions yet identifying them via traditional methods is a costly and laborious process.
The AlphaFold Breakthrough
We explore the impact of AlphaFold2, the AI predictive model from Google DeepMind that won its creators the 2024 Nobel Prize for Chemistry.
→ Speed: AI can predict protein structures in minutes rather than years.
→ Accuracy: The model was trained on ~140,000 structures to achieve high predictive accuracy.
→ Efficiency: Experts believe AI could shorten the preclinical research phase by approximately two years.
The Global AI Value ChainWe examine the commercial infrastructure that powers this revolution.
To sustain these advancements, a complex supply chain is required:
→ Companies like Thermo Fisher and Idexx are integrating AI into R&D and diagnostics to increase efficiency.
→ Firms like ASML and TSMC build the essential chips.
→ Hyperscalers such as Microsoft, Amazon, and Alphabet provide the necessary capacity for complex simulations.
"While researchers are using AI to decode the body’s source code, the commercial side is using it to fix a broken, expensive system."
